In vitro fertilization in the polycystic ovary syndrome patient: An update

Clinical Obstetrics and Gynecology

Volumn 50, Issue 1, 2007, Pages 268-276

  Lin, Kathleen ^a   Coutifaris, Christos ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; ESTRADIOL; ESTROFEM; GONADORELIN AGONIST; LEUPRORELIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ACNE; ANOVULATION; CLINICAL ASSESSMENT; DRUG DOSE REDUCTION; ESTRADIOL BLOOD LEVEL; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GRANULOSA CELL; HIRSUTISM; HUMAN; HYPERANDROGENISM; LABORATORY TEST; MENSTRUAL CYCLE; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; REVIEW; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; POLYCYSTIC OVARY SYNDROME;

EID: 33847238795     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3180305fe4     Document Type: Review

References (43)

1. Navot D, Bergh PA, et al. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-261.
2. MacDougall MJ, Tan SL, et al. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod. 1993;8:233-237.
3. Chen D, Burmeister L, et al. Ovarian hyperstimulation syndrome: strategies for prevention. Reprod Biomed Online. 2003;7:43-49.
4. Leman P, Greene S, et al. Simple light-weight disposable continuous positive airways pressure mask to effectively treat acute pulmonary oedema: randomized controlled trial. Emerg Med Australas. 2005;17:224-230.
5. Tummon I, Gavrilova-Jordan L, et al. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand. 2005;84:611-616.
6. Jabara S, Coutifaris C. In vitro fertilization in the PCOS patient: clinical considerations. Semin Reprod Med. 2003;21:317-324.
7. Asch RH, Li HP, et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991;6:1395-1399.
8. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559-577.
9. Damewood MD, Shen W, et al. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril. 1989;52:398-400.
10. Agrawal R, Jacobs H, et al. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril. 2002;78:1164-1169.
11. Wang TH, Horng SG, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002;87:3300-3308.
12. Damario MA, Barmat L, et al. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod. 1997;12:2359-2365.
13. Biljan MM, Mahutte NG, et al. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril. 1998;70:1063-1069.
14. Lewit N, Kol S, et al. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Hum Reprod. 1996;11:1399-1402.
15. De Jong D, Van Hooren EG, et al. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. J Assist Reprod Genet. 2001;18:30-33.
16. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1-5.
17. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000;15:1965-1968.
18. Fauser BC, de Jong D, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709-715.
19. Humaidan P, Bredkjaer HE, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213-1220.
20. Griesinger G, Diedrich K, et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159-168.
21. Kolibianakis EM, Schultze-Mosgau A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887-2892.
22. Beckers NG, Macklon NS, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88:4186-4192.
23. Babayof R, Margalioth EJ, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260-1265.
24. Kashyap S, Wells GA, et al. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod. 2004;19:2474-2483.
25. Costello MF, Chapman M, et al. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod. 2006;21:1387-1399.
26. Legro RS, et al, for the Reproductive Medicine Network. Improvement in live births with clomiphene citrate and metformin, alone and in combination, in infertile women with polycystic ovary syndrome. Fertil Steril. 2006;86 (suppl S):S1.
27. Moll E, Bossuyt PM, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332:1485.
28. Tang T, Glanville J, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21:1416-1425.
29. Trounson A, Wood C, et al. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril. 1994;62:353-362.
30. Robinson TW, Roberts AM. Effects of exogenous surfactant on gas exchange and compliance in rabbits after meconium aspiration. Pediatr Pulmonol. 2002;33:117-123.
31. Mikkelsen AL. Strategies in human in-vitro maturation and their clinical outcome. Reprod Biomed Online. 2005;10:593-599.
32. Chian RC, Buckett WM, et al. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod. 2000;15:165-170.
33. Mikkelsen AL, Lindenberg S. Benefit of FSH priming of women with PCOS to the in vitro maturation procedure and the outcome: a randomized prospective study. Reproduction. 2001;122:587-592.
34. Lin YH, Hwang JL, et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod. 2003;18:1632-1636.
35. Hwang JL, Lin YH, et al. In vitro maturation and fertilization of immature oocytes: a comparative study of fertilization techniques. J Assist Reprod Genet. 2000;17:39-43.
36. Chian RC. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online. 2004;8:547-552.
37. Cha KY, Chung HM, et al. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril. 2005;83:1461-1465.
38. Le Du A, Kadoch IJ, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod. 2005;20:420-424.
39. Child TJ, Phillips SJ, et al. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol. 2002;100:665-670.
40. Child TJ, Abdul-Jalil AK, et al. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril. 2001;76:936-942.
41. Li Y, et al. Confocal microscopic analysis of the spindle and chromosome configurations of human oocytes matured in vitro. Fertil Steril. 2006;85:827-832.
42. Chian RC, Lim JH, et al. State of the art in in-vitro oocyte maturation. Curr Opin Obstet Gynecol. 2004;16:211-219.
43. Borghol N, et al. Epigenetic status of the H19 locus in human oocytes following in vitro maturation. Genomics. 2006;87:417-426.